Dianthus Therapeutics Inc DE

For the period ended Dec 31, 2023. Filed Mar 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 21, 2024

DNTH$90.00+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

		DIANTHUS THERAPEUTICS, INC.
Date:	March 21, 2024	By:	/s/ Ryan Savitz
			Ryan Savitz
			Chief Financial Officer and Chief Business Officer
			(Principal Financial Officer)

Marino Garcia
Signature	Title	Date
/s/ Marino Garcia	President, Chief Executive Officer and Director(Principal Executive Officer)	March 21, 2024
/s/ Ryan Savitz	Chief Financial Officer and Chief Business Officer(Principal Financial Officer)	March 21, 2024
Ryan Savitz
/s/ Edward Carr	Chief Accounting Officer (Principal Accounting Officer)	March 21, 2024
Edward Carr
/s/ Leon O. Moulder, Jr.	Director and Chair of the Board	March 21, 2024
Leon O. Moulder, Jr.
/s/ Tomas Kiselak	Director	March 21, 2024
Tomas Kiselak
/s/ Alison F. Lawton	Director	March 21, 2024
Alison F. Lawton
/s/ Anne McGeorge	Director	March 21, 2024
Anne McGeorge
/s/ Lei Meng	Director	March 21, 2024
Lei Meng
/s/ Paula Soteropoulos	Director	March 21, 2024
Paula Soteropoulos
/s/ Jonathan Violin, Ph.D.	Director	March 21, 2024
Jonathan Violin, Ph.D.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.